Imaging services provider RadNet said it has joined the Imaging and Genetic Biomarkers for Alzheimer's Disease (ImaGene) study.
Launched in 2008 by the Mary S. Easton Center for Alzheimer's Disease Research at the University of California, Los Angeles, the observational biomarker study is investigating the potential interactions between genes, proteins, amyloid PET imaging, and MRI brain imaging in aging and the prodromal stages of Alzheimer's disease. The study is sponsored by the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development, as well as the U.S. National Institute on Aging. It's also supported in part by GE Healthcare; GE's Vizamyl PET tracer for beta-amyloid detection is being used in the trial to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment.
Patients who meet the study protocol's criteria will have a PET/CT scan with Vizamyl at RadNet's Liberty Pacific Advanced Imaging in Los Angeles or Beverly Tower Advanced Imaging in Beverly Hills, CA.
